BMY241213C65000
- 0.01
- 0.000.00%
Bristol-Myers Squibb Newsroom
Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma In The Context Of The Ongoing Strategic Review Of Century's...
Express News | Century Therapeutics - to Evaluate Opportunities in Aml and Multiple Myeloma
Express News | Century Therapeutics - Termination Effective March 12, 2025
Express News | Century Therapeutics- Bms Notified Co on Dec 12 to Terminate Collaboration Agreement With Century Therapeutics
Weekly Buzz: Tech stocks hit high scores on ominous day
Express News | Bristol-Myers Squibb Co Files for Mixed Shelf; Size Not Disclosed - SEC Filing
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Market Mixed on Friday the 13th | Livestock
Bristol-Myers Squibb Hits 4-week Low
Thursday Ends in Index Declines | Wall Street Today
Why Bristol-Myers Squibb (BMY) Is Among the Best Long-Term Dividend Stocks to Invest in Right Now
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
Bristol-Myers Squibb To Go Ex-Dividend On January 3rd, 2025 With 0.62 USD Dividend Per Share
Express News | Bristol-Myers Squibb Co - Bristol Myers Squibb Declares Quarterly Dividend of $0.62 per Share
Bristol Myers Squibb Announces Dividend Increase >BMY
Press Release: Bristol Myers Squibb Announces Dividend Increase
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Berenberg Bank Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60
Berenberg Bank Remains a Hold on Bristol-Myers Squibb (BMY)